Content-Length: 251738 | pFad | https://cancerletter.com/clinical-roundup/20241213_9k/

Yescarta demonstrates improved outcomes for r/r LBCL - The Cancer Letter

The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Yescarta demonstrates improved outcomes for r/r LBCL

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Kite announced findings from three new analyses for Yescarta (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or refractory large B-cell lymphoma, which were presented at 66th American Society of Hematology annual meeting.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Donald, Dunbar, Lee, Michaelis receive 2022 ASH Exemplary Service Award

The American Society of Hematology named Chancellor Donald, of Tulane University, Cynthia E. Dunbar, of NIH, Stephanie Lee, of Fred Hutchinson Cancer Center, and Laura Michaelis, of Medical College of Wisconsin, recipients of the 2022 Exemplary Service Award for their exceptional service and dedication to the Society and the field of hematology through their tireless work leading ASH’s response to COVID-19.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account









 ApplySandwichStrip

pFad - (p)hone/(F)rame/(a)nonymizer/(d)eclutterfier!      Saves Data!


--- a PPN by Garber Painting Akron. With Image Size Reduction included!

Fetched URL: https://cancerletter.com/clinical-roundup/20241213_9k/

Alternative Proxies:

Alternative Proxy

pFad Proxy

pFad v3 Proxy

pFad v4 Proxy